The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2023 | Retrospective study on the outcomes of patients with myeloma treated with cilta-cel and ide-cel
Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, shares the results of a retrospective study evaluating the outcomes of patients with relapsed/refractory (R/R) multiple myeloma treated with BCMA-directed CAR-T therapies, commenting on the efficacy and toxicities of these therapies. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Therakos/Mallinckrodt: Honoraria; Sanofi: Honoraria; Astellas: Honoraria; JAZZ pharmaceuticals: Honoraria; Biocodex: Honoraria; Janssen: Honoraria; Takeda: Honoraria; Novartis: Honoraria; Gilead: Honoraria; Celgene-BMS: Honoraria.
